Illumina Inc. ($ILMN) Stock Forecast: Up 25.0% Today

What is Illumina Inc.?

Illumina (NASDAQ: ILMN) is a leading company in the field of DNA sequencing, providing innovative solutions for genetic analysis. The stock had a strong bullish movement today.

Why is Illumina Inc. going up?

ILMN stock is up 25.0% on Oct 31, 2025 19:51

• Illumina's stock surged due to better-than-expected third-quarter earnings, with adjusted earnings surpassing consensus estimates.
• The bullish sentiment towards Illumina was further reinforced by deep-pocketed investors adopting a positive approach towards the company, as revealed by options trading data.
• The company's ability to beat both earnings and revenue estimates for the third quarter showcased its strong performance and potential for future growth, contributing to the stock's upward momentum.
• Overall, Illumina's impressive financial results and market sentiment drove the stock higher, indicating investor confidence in the company's strategic direction and growth prospects in the DNA sequencing industry.

ILMN Price Chart

ILMN Technical Analysis

ILMN News

Illumina Options Trading: A Deep Dive into Market Sentiment - Illumina ( NASDAQ:ILMN )

Deep-pocketed investors have adopted a bullish approach towards Illumina ( NASDAQ:ILMN ) , and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.

https://www.benzinga.com/insights/options/25/10/48567755/illumina-options-trading-a-deep-dive-into-market-sentiment

Why Is Illumina Stock Soaring Today - Illumina ( NASDAQ:ILMN )

Illumina Inc. ( NASDAQ:ILMN ) stock is trading higher after the company reported better-than-expected third-quarter earnings. The DNA sequencing company reported adjusted earnings of $1.34 per share, beating the consensus of $1.17.

https://www.benzinga.com/markets/earnings/25/10/48565485/dna-sequencing-firm-illumina-sees-strong-clinical-market-momentum-stock-soars

Illumina ( ILMN ) Beats Q3 Earnings and Revenue Estimates

Illumina (ILMN) delivered earnings and revenue surprises of +15.52% and +1.73%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2782032/illumina-ilmn-beats-q3-earnings-and-revenue-estimates

Trending Today

Illumina Inc. ($ILMN) Stock Forecast: Up 25.0% Today

First Solar Inc. ($FSLR) Stock Forecast: Up 13.2% Today

MicroStrategy ($MSTR) Stock Forecast: Up 6.0% Today

DexCom Inc. ($DXCM) Stock Forecast: Down 14.3% Today

Reddit Inc ($RDDT) Stock Forecast: Up 7.8% Today

Cloudflare Inc. ($NET) Stock Forecast: Up 12.5% Today

Amazon.com Inc. ($AMZN) Stock Forecast: Up 10.4% Today

Dogecoin ($DOGE) Crypto Forecast: Up 5.6% Today

XRP ($XRP) Crypto Forecast: Up 5.3% Today

Ethereum ($ETH) Crypto Forecast: Up 5.0% Today

Illumina Inc. Price History

16.09.2025 - ILMN Stock was up 5.2%

• The reasons behind the bullish movement in ILMN stock are:
• Favorable comparisons with another stock, potentially positioning ILMN as the more valuable choice.
• Investors seeking promising opportunities in the market may have been attracted by this comparison, resulting in heightened buying activity for ILMN shares.
• Positive perceptions of ILMN's technology and competitive position compared to its rival could have spurred increased demand for the stock.

15.08.2025 - ILMN Stock was up 5.2%

• The bullish movement in ILMN stock today can be attributed to the positive market sentiment surrounding the launch of the Illumina Protein Prep Assay.
• The rollout of this new product is expected to enhance Illumina's capabilities in multiomics research, which could lead to significant advancements in understanding various diseases.
• Investors are likely optimistic about the potential revenue growth and market expansion opportunities that the Illumina Protein Prep Assay could bring to the company, driving the stock's upward trajectory.

01.07.2025 - ILMN Stock was down 10.2%

• Despite Illumina (ILMN) surpassing earnings and revenue estimates in Q2, the stock experienced a strong bearish movement.
• The market may have reacted negatively due to profit-taking by investors after a period of strong performance leading up to the earnings release.
• Additionally, there could be concerns about future growth prospects or guidance provided by the company that did not meet heightened market expectations.
• It's possible that some investors were expecting even better results, leading to a sell-off in the stock despite the positive earnings surprise.

01.07.2025 - ILMN Stock was down 8.7%

• Despite reporting better-than-expected earnings and revenues for the second quarter, Illumina's stock experienced a significant bearish movement.
• The market's reaction may have been influenced by profit-taking behaviors, potentially following a period of favorable outcomes, leading to a temporary decline in the stock price.
• The results slightly below some investors' expectations could have induced a sense of disappointment, contributing to the bearish sentiment in the market.
• Nevertheless, the observed bearish movement could be a brief response to the earnings report, and the long-term outlook for Illumina appears promising, given its strong position in the biotechnology sector.

22.06.2025 - ILMN Stock was up 5.5%

• Despite differing views, ILMN saw a strong bullish movement today.
• The varying opinions may have contributed to investor uncertainty and increased volatility.
• Positive aspects of Illumina's business, like innovative technologies and market leadership, likely drove the bullish momentum.
• Market participants may have favored ILMN over HRMY due to factors such as growth potential, financial performance, or market positioning.

08.09.2025 - ILMN Stock was down 5.5%

• The bearish movement in ILMN today could be attributed to profit-taking by investors after a period of strong performance.
• The upcoming earnings report, despite expectations of a beat, might have led to some uncertainty among investors, causing a sell-off.
• The partnership with pharma companies for CDx development is a positive long-term move, but short-term investors might be reacting cautiously to the news, contributing to the bearish trend.
• Overall, the bearish movement in ILMN today seems to be a short-term market correction rather than a reflection of the company's fundamentals.

06.07.2025 - ILMN Stock was down 5.4%

• The bearish movement in ILMN stock today can be attributed to the settlement with the Department of Justice (DOJ) and Veterans to end a whistleblower lawsuit, leading to a significant financial payout.
• Despite reporting better-than-expected earnings for the second quarter and surpassing revenue estimates, the negative impact of the settlement on the company's finances likely overshadowed the positive financial results.
• Investors may be concerned about the implications of the settlement on Illumina's reputation and future legal challenges, leading to a sell-off of the stock.
• The market reaction reflects the delicate balance between financial performance and legal risks in the biotechnology sector, highlighting the importance of maintaining regulatory compliance and ethical standards to sustain investor confidence.

23.06.2025 - ILMN Stock was up 5.4%

• The positive movement in ILMN today could be linked to optimistic outlooks in the biotech field and potential growth possibilities.
• Speculations around Ark Invest purchasing shares of NVIDIA Corp amidst concerns regarding an AI initiative might have stirred confidence in the tech industry, indirectly influencing companies like Illumina.
• Detailed examination of Illumina's internal structure may have been somewhat overshadowed by broader market tendencies and favorable industry updates, contributing to the stock's upwards trend.
• Investors seem to view Illumina as a key player in the biotech sector, especially with ongoing advancements in genetic technologies and research.

31.09.2025 - ILMN Stock was up 14.2%

• Exceeded earnings and revenue expectations for the third quarter.
• Positive surprise indicates strong demand for its products and services.
• Investors are optimistic about its future outlook.
• Market's bullish movement on ILMN today could be attributed to strong financial performance and growth opportunities in the genomics industry.

31.09.2025 - ILMN Stock was up 23.9%

• Illumina's stock soared today following better-than-expected third-quarter earnings.
• The company reported adjusted earnings of $1.34 per share, exceeding the consensus of $1.17, which contributed to the bullish movement.
• Positive earnings and revenue surprises of +15.52% and +1.73%, respectively, for the quarter ended September 2025, further fueled investor confidence in Illumina's growth prospects.
• Overall, the strong financial performance and optimistic outlook from Illumina's earnings likely drove the bullish movement in the stock today.

31.09.2025 - ILMN Stock was up 25.0%

• Illumina's stock surged due to better-than-expected third-quarter earnings, with adjusted earnings surpassing consensus estimates.
• The bullish sentiment towards Illumina was further reinforced by deep-pocketed investors adopting a positive approach towards the company, as revealed by options trading data.
• The company's ability to beat both earnings and revenue estimates for the third quarter showcased its strong performance and potential for future growth, contributing to the stock's upward momentum.
• Overall, Illumina's impressive financial results and market sentiment drove the stock higher, indicating investor confidence in the company's strategic direction and growth prospects in the DNA sequencing industry.

01.09.2025 - ILMN Stock was up 6.5%

• Illumina's bullish movement today could be attributed to positive comparisons highlighting its value and growth potential in the precision oncology and biomedical sectors.
• Positive assessments of Illumina's growth momentum and value compared to other companies in the industry may have sparked investor interest and contributed to the stock's upward trajectory.
• Investors may view Illumina as a strong contender in the precision medicine space, driving demand for the stock and fueling its bullish movement.